Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04920617
Status:
RECRUITING
Last Update Posted:
2023-04-07
First Post:
2021-05-28
Brief Title:
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide in Subjects With RelapsedRefractory Diffuse Large B-Cell Lymphoma
Sponsor:
ImmunoVaccine Technologies Inc IMV Inc
Organization:
ImmunoVaccine Technologies Inc IMV Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-18
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-04
Completion Date Type:
ESTIMATED
First Submit Date:
2021-05-28
First Submit QC Date:
June 3 2021
Study First Post Date:
2021-06-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-05
Last Update Post Date:
2023-04-07
Last Update Post Date Type:
ACTUAL